<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: <z:chebi fb="0" ids="26831">Sulfonylureas</z:chebi> (SUs) may impair outcome in patients with <z:hpo ids='HP_0011009'>acute</z:hpo> coronary syndrome </plain></SENT>
<SENT sid="1" pm="."><plain>Most experimental studies of the myocardial effects of SU treatment are performed in non-diabetic models </plain></SENT>
<SENT sid="2" pm="."><plain>We compared the effect of two widely used SUs, <z:chebi fb="0" ids="5441">glibenclamide</z:chebi> (gb) and <z:chebi fb="0" ids="31654">gliclazide</z:chebi> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">gc</z:e>), with high and low myocardial K(ATP) channel affinity, respectively, at therapeutic concentrations on <z:mpath ids='MPATH_124'>infarct</z:mpath> size, left ventricular (LV) function and myocardial <z:chebi fb="15" ids="28087">glycogen</z:chebi>, <z:chebi fb="4" ids="24996">lactate</z:chebi> and alanine content before and after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>/reperfusion (I/R) </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Non-diabetic Wistar and diabetic Goto-Kakizaki rat hearts were investigated in a Langendorff preparation </plain></SENT>
<SENT sid="4" pm="."><plain>Gb (0.1 μmol/l) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">gc</z:e> (1.0 μmol/l) were administrated throughout the study </plain></SENT>
<SENT sid="5" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> size was evaluated after 120 min of reperfusion </plain></SENT>
<SENT sid="6" pm="."><plain>Myocardial metabolite content was measured before and after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: <z:mpath ids='MPATH_124'>Infarct</z:mpath> size was smaller in diabetic hearts than in non-diabetic hearts (0.33 ± 0.03 vs 0.51 ± 0.05, p &lt; 0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>Gb increased <z:mpath ids='MPATH_124'>infarct</z:mpath> size (0.54 ± 0.04 vs 0.33 ± 0.03, p &lt; 0.05) and reduced post-ischaemic LV developed pressure (60 ± 3 vs 76 ± 3 mmHg, p &lt; 0.05) and coronary flow (4.9 ± 0.5 vs 7.1 ± 0.4 ml min(-1) g(-1), p &lt; 0.05) in gb-treated diabetic rats compared with untreated diabetic rats </plain></SENT>
<SENT sid="9" pm="."><plain>On comparing gb-treated diabetic rats with untreated diabetic rats, <z:chebi fb="15" ids="28087">glycogen</z:chebi> content was reduced before (9.1 ± 0.6 vs 13.6 ± 1.0 nmol/mg wet weight, p &lt; 0.01) and after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> (0.9 ± 0.2 vs 1.8 ± 0.2 nmol/mg wet weight, p &lt; 0.05), and <z:chebi fb="4" ids="24996">lactate</z:chebi> (4.8 ± 0.4 vs 3.2 ± 0.3 nmol/mg wet weight, p &lt; 0.01) and alanine (1.38 ± 0.12 vs 0.96 ± 0.09 nmol/mg wet weight, p &lt; 0.05) contents were increased during reperfusion </plain></SENT>
<SENT sid="10" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">Gc</z:e>-treatment of diabetic and non-diabetic rats did not affect any of the measured variables </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS/INTERPRETATIONS: Gb, but not <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">gc</z:e>, exacerbates I/R injury and deteriorates LV function in diabetic hearts </plain></SENT>
<SENT sid="12" pm="."><plain>These effects of gb on diabetic hearts may be due to detrimental effects on myocardial carbohydrate metabolism </plain></SENT>
</text></document>